%PDF-1.4
%
89 0 obj
<>
endobj
86 0 obj
<>
endobj
170 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-04-13T14:48:18Z
2024-03-28T15:25:49-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T15:25:49-07:00
application/pdf
Heather
2003-497.may
uuid:e0709a7d-1dd1-11b2-0a00-e708277d8900
uuid:e0709a7f-1dd1-11b2-0a00-d30000000000
endstream
endobj
75 0 obj
<>
endobj
76 0 obj
<>
endobj
90 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 55 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 57 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 59 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 61 0 R/Type/Page>>
endobj
15 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 63 0 R/Type/Page>>
endobj
28 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 65 0 R/Type/Page>>
endobj
41 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 67 0 R/Type/Page>>
endobj
44 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 69 0 R/Type/Page>>
endobj
201 0 obj
[205 0 R]
endobj
202 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.8 g
/T1_0 18 Tf
0.6114 0.7912 -0.7912 0.6114 35.383 35.2215 Tm
(Personal, non-commercial use only. The Journal of Rheumatology. Copyrigh\
t \251 2004. All rights reserved.)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.3138 Tw 10 0 0 10 54 713.1616 Tm
(of the occurrence of adverse reactions possibly due to)Tj
0.2113 Tw 0 -1.2 TD
[(product-specific immunogenicity)64.8 (. It is also desirable that)]TJ
0.00439 Tc 0.3705 Tw T*
(immunogenic potentials of hylan G-F 20 and sodium)Tj
-0.00011 Tc 0.02499 Tw T*
(hyaluronate products should be strictly distinguished.)Tj
/T1_2 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 61 643.1616 Tm
[(1.)-875.1 (American College of Rheumatology Subcommittee on)]TJ
1.675 -1.25 Td
(Osteoarthritis Guidelines. Recommendation for the medical)Tj
0 -1.25 TD
(management of osteoarthritis of the hip and knee: 2000 update.)Tj
T*
(Arthritis Rheum 2000;43:1905-15.)Tj
-1.675 -1.25 Td
[(2.)-875.1 (Adams ME, Lussier )54.8 (AJ, Peyron JG. )54.8 (A)-220.1 (risk-benefit assessment of)]TJ
1.675 -1.25 Td
(injections of hyaluronan and its derivatives in the treatment of)Tj
T*
[(osteoarthritis of the knee. Drug Saf 2000;23:1)36.8 (15-30.)]TJ
-1.675 -1.25 Td
[(3.)-875.1 (Marshall KW)91.7 (. Intra-articular hyaluronan therapy)64.8 (. Curr Opin)]TJ
1.675 -1.25 Td
(Rheumatol 2000;12:468-74.)Tj
-1.675 -1.25 Td
[(4.)-875.1 (Puttick MP)110.7 (, )17.7 (W)79.9 (ade JP)110.7 (, Chalmers )54.8 (A, Connell DG, Rango KK. )54.8 (Acute)]TJ
1.675 -1.25 Td
(local reactions after intraarticular hylan for osteoarthritis of the)Tj
T*
[(knee. J Rheumatol 1995;22:131)36.8 (1-4.)]TJ
-1.675 -1.25 Td
[(5.)-875.1 (Allen E, Krohn K. )54.8 (Adverse reaction to hylan GF 20 [letter]. )]TJ
1.675 -1.25 Td
(J Rheumatol 2000;27:1572.)Tj
-1.675 -1.25 Td
[(6.)-875.1 (Martens PB. Bilateral symmetric inflammatory reaction to hylan )]TJ
1.675 -1.25 Td
[(G-F 20 injection. )54.8 (Arthritis Rheum 2001;44:978-9.)]TJ
-1.675 -1.25 Td
[(7.)-875.1 (Leopold SS, )17.7 (W)39.8 (inston J, )17.7 (W)79.9 (arme LC, Pettis PD, Shott S. Increased)]TJ
1.675 -1.25 Td
(frequency of acute local reaction to intra-articular hylan GF-20)Tj
T*
(\(Synvisc\) in patients receiving more than one course of treatment. )Tj
0 Tc T*
[(J Bone Joint Sur)17.8 (g )54.8 (Am 2002;84:1619-23.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(8.)-875.1 (Pullman-Mooar S, Mooar P)110.7 (, Sieck M, Clayburne G, Schumacher)]TJ
1.675 -1.25 Td
[(HR. )54.8 (Are there distinctive inflammatory flares after hylan G-F 20)]TJ
T*
[(intraarticular injections? J Rheumatol 2002;29:261)36.8 (1-4.)]TJ
-1.675 -1.25 Td
[(9.)-875.1 (Balazs EA, Bland P)91.7 (A, Denlinger JL, et al. Matrix engineering.)]TJ
1.675 -1.25 Td
(Blood Coagl Fibrinoly 1991;2:173-8.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (Bucher )17.7 (W)91.9 (, Otto )17.7 (T)74 (, Hambur)17.7 (ger MI. Dif)17.7 (ferentiation of hyaluronate)]TJ
2.175 -1.25 Td
[(products by qualitative dif)17.7 (ferences in their immunogenicity in)]TJ
T*
(rabbits: possible mechanism for product specific severe adverse)Tj
T*
[(reactions? Comment on the article by Martens [letter]. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 2002;46:2543-4.)Tj
-0.00011 Tc -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Richter )54.8 (A)79.8 (W)91.8 (, R)39.7 (yde EM, Zetterstrom EO. Non-immunogenicity of a)]TJ
2.1381 -1.25 Td
[(purified sodium hyaluronate preparation in man. Int )54.8 (Arch )54.8 (Aller)17.7 (gy)]TJ
T*
(Appl Immunol 1979;59:45-8.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Goa KL, Benfield P)110.7 (. Hyaluronic acid. )54.8 (A)-220.1 (review of its pharmacology)]TJ
2.175 -1.25 Td
[(and use as a sur)17.7 (gical aid in ophthalmology)64.8 (, and its therapeutic)]TJ
T*
(potential in joint disease and wound healing. Drugs )Tj
0 Tc 0 Tw T*
(1994;47:536-66.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(13.)-875.1 (Nagagawa K, Nozaki H, Sugawara H, )36.8 (Y)99.8 (amaguchi )17.7 (T)74 (.)-0.1 ( )54.8 (Antigenicity)]TJ
2.175 -1.25 Td
(studies on sodium hyaluronate \(SPH\). I. Experiments in guinea pig)Tj
T*
[([Japanese]. Jpn Pharmacol )17.7 (Ther 1984;12:141-50.)]TJ
-2.175 -1.25 Td
[(14.)-875.1 (Nagagawa K, Nozaki H, Sugawara H, )36.8 (Y)99.8 (amaguchi )17.7 (T)74 (.)-0.1 ( )54.8 (Antigenicity)]TJ
2.175 -1.25 Td
(studies on sodium hyaluronate \(SPH\). II. Experiments in mouse)Tj
T*
[(and rabbit [Japanese]. Jpn Pharmacol )17.7 (Ther 1984;12:151-61.)]TJ
-2.175 -1.25 Td
[(15.)-875.1 (Itagaki H, Hagino S, Kuramoto M, Kato S. )54.8 (Antigenicity study of)]TJ
2.175 -1.25 Td
(sodium hyaluronate \(SL-1010\) in mice and guinea pigs [Japanese].)Tj
T*
[(Jpn Pharmacol )17.7 (Ther 1991;19 Suppl 1:S137-52.)]TJ
-0.0051 Tc -2.175 -1.25 Td
[(1)-5.1 (6)-5.1 (.)-880.1 (Matsuura )17.7 (T)74 (, Kurio )17.7 (W)91.8 (, Uechi S, Nadai )17.7 (T)74 (, Ishihara R, Miyoshi )17.7 (T)74 (.)]TJ
2.175 -1.25 Td
(Antigenicity study of high molecular weight sodium hyaluronate)Tj
T*
[(\(NRD101\) [Japanese]. Jpn Pharmacol )17.6 (Ther 1994;22 Suppl:S637-4)-5.1 (9)-5.1 (.)]TJ
-0.00011 Tc 30.825 68.921 Td
[(17.)-875.1 (Choquet-Kastylevsky G, Descotes J. )17.7 (V)110.8 (alue of animal models for)]TJ
2.175 -1.25 Td
(predicting hypersensitivity reactions to medicinal products.)Tj
0 Tc T*
[(T)70 (oxicology 1998;129:27-35.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(18.)-875.1 (Nagami K, Matsumoto H, Maki E, et al. Experimental methods for)]TJ
2.175 -1.25 Td
(immunization and challenge in antigenicity studies in guinea pigs. )Tj
T*
[(J )17.7 (T)69.9 (oxicol Sci 1995;20:579-94.)]TJ
-2.175 -1.25 Td
[(19.)-875.1 (Sasaki M, Miyazaki )36.8 (Y)128.9 (,)-0.1 ( )17.7 (T)69.9 (akahashi )17.7 (T)74 (. Hylan G-F 20 induces delayed)]TJ
2.175 -1.25 Td
[(foreign body inflammation in guinea pigs and rabbits. )17.7 (T)69.9 (oxicol)]TJ
T*
(Pathol 2003;31:321-5.)Tj
-2.175 -1.25 Td
[(20.)-875.1 (Norton )54.8 (AJ, Jordan S, )36.8 (Y)99.8 (eomans P)110.7 (. Brief high-temperature heat)]TJ
2.175 -1.25 Td
[(denaturation \(pressure cooking\): a simple and ef)17.7 (fective method of)]TJ
T*
(antigen retrieval for routinely processed tissues. J Pathol)Tj
0 Tc 0 Tw T*
(1994;173:371-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(21.)-875.1 (W)79.9 (atanabe N, Ovary Z. )54.8 (Antigen and antibody detection by in vivo)]TJ
2.175 -1.25 Td
(methods: a reevaluation of passive cutaneous anaphylactic)Tj
T*
(reactions. J Immunol Methods 1977;14:380-90.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (Crowther JR. Stages in ELISA. 1. Solid-phase. In: Crowther JR.)]TJ
2.175 -1.25 Td
[(editor)54.8 (. ELISA: theory and practice. )17.7 (T)69.9 (otawa, New Jersey: Humana)]TJ
T*
(Press; 1995:63-8.)Tj
-2.175 -1.25 Td
[(23.)-875.1 (Chichibu K, Matsuura )17.7 (T)74 (, Shichijo S, )36.8 (Y)99.8 (okoyama MM. )54.8 (Assay of)]TJ
2.175 -1.25 Td
[(serum hyaluronic acid in clinical application. Clin Chim )54.8 (Acta)]TJ
0 Tc 0 Tw T*
(1989;181:317-24.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(24.)-875.1 (Hambur)17.7 (ger MI, Lakhanpal S, Mooar P)91.7 (A, Oster D. Intra-articular)]TJ
2.175 -1.25 Td
(hyaluronans: a review of product-specific safety profiles. Semin)Tj
T*
(Arthritis Rheum 2003;32:296-309.)Tj
-2.175 -1.25 Td
[(25.)-875.1 (Humphrey JH. )17.7 (T)69.9 (olerogenic or immunogenic activity of )]TJ
2.175 -1.25 Td
(hapten-conjugated polysaccharides correlated with cellular )Tj
T*
[(localization. Eur J Immunol 1981;1)36.8 (1:212-20.)]TJ
-2.175 -1.25 Td
[(26.)-875.1 (Snapper CM, Mond JJ. )54.8 (A)-220.1 (model for induction of )17.7 (T)-257.1 (cell-independent)]TJ
2.175 -1.25 Td
(humoral immunity in response to polysaccharide antigens. )Tj
T*
(J Immunol 1996;157:2229-33.)Tj
-2.175 -1.25 Td
[(27.)-875.1 (Piacquadio D, Jarcho M, Goltz R. Evaluation of hylan b gel as a)]TJ
2.175 -1.25 Td
[(soft-tissue augmentation implant material. J )54.8 (Am )54.8 (Acad Dermatol)]TJ
0 Tc 0 Tw T*
(1997;36:544-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(28.)-875.1 (Rihova B, Riha I. Immnunological problems of polymer)19.7 (-bound)]TJ
2.175 -1.25 Td
[(drugs. Crit Rev )17.7 (Ther Drug Carrier Syst 1985;1:31)36.8 (1-74.)]TJ
-2.175 -1.25 Td
[(29.)-875.1 (Howson P)110.7 (, Shepard N, Mitchell N. )17.7 (The antigen induced arthritis)]TJ
2.175 -1.25 Td
[(model: )17.7 (The relevance of the method of induction to its use as a)]TJ
T*
(model of human disease. J Rheumatol 1986;13:379-390.)Tj
-2.175 -1.25 Td
[(30.)-875.1 (Synvisc premarket approval application: summary of safety and)]TJ
2.175 -1.25 Td
[(ef)17.7 (fectiveness data. Internet. [cited 2004 January 21] )54.8 (A)74 (vailable from:)]TJ
0 Tw T*
[(http://www)64.8 (.fda.gov/cdrh/pdf/p940015.pdf.)]TJ
0.02499 Tw -2.175 -1.25 Td
[(31.)-875.1 (Adams ME, O\325Hanlon D, Puttick MP)110.7 (, Chalmers )54.8 (A, )17.7 (W)79.9 (ade JP)110.8 (. )54.8 (Acute)]TJ
2.175 -1.25 Td
(local reactions after intraarticular hylan for osteoarthritis of the)Tj
T*
(knee. J Rheumatol 1996;23:944-5.)Tj
-2.175 -1.25 Td
[(32.)-875.1 (Punzi L. )17.7 (The complexity of the mechanisms of action of)]TJ
2.175 -1.25 Td
(hyaluronan in joint diseases. Clin Exp Rheumatol 2001;19:242-6.)Tj
-2.175 -1.25 Td
[(33.)-875.1 (Ghosh P)110.7 (, Guidolin D. Potential mechanism of action of )]TJ
2.175 -1.25 Td
[(intra-articular hyaluronan therapy in osteoarthritis: )54.8 (Are the ef)17.7 (fects)]TJ
T*
[(molecular weight dependent? Semin )54.8 (Arthritis Rheum )]TJ
0 Tc 0 Tw T*
(2002;32:10-37.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(34.)-875.1 (Lowe NJ, Maxwell CA, Lowe P)110.7 (, Duick MG, Shah K. Hyaluronic)]TJ
2.175 -1.25 Td
[(acid skin fillers: )54.8 (Adverse reaction and skin testing. J )54.8 (Am )54.8 (Acad)]TJ
T*
(Dermatol 2001;45:930-3.)Tj
-2.175 -1.25 Td
[(35.)-875.1 (Micheels P)110.7 (. Human anti-hyaluronic acid antibodies: is it possible?)]TJ
0 Tc 2.175 -1.25 Td
[(Dermatol Sur)17.8 (g 2001;27:185-91.)]TJ
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_3 1 Tf
-0.00011 Tc 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2004; 31:5)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(950)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.09 396.47 -10.83 re
f*
0.5 w
109.25 59.09 396.47 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
69 0 obj
<>stream
8;Z\6;3li"#ikn#j?!1LRLkSF<45$gT!R7QFbC;-kl.YrrMsLAYQ)R&2S=5.ml"E3
/uu*5MjsVuqeH;27aOpF@XK&'`H$eIhn4A(XetgnIXQciS;lo`9%Z$E8g$WXfAQCRmt1RWAk>614!1,J5Sk6_&g:<9Y:N2U;r-1k,imN0p6sXF"aU!"V-6HCXU;u7VTGNk"8=(
^*MU/,jpN4;AgAQ.+0(@]*'_82jNdX#2\S#(O(TR:_[&hQbBDI)435#gH6B)>Q22l
61e@",/tRR$-`jp!h2N=.64F,&<^()h[3jCV`O&WZuZV9_Q!g/UYea9C7h@p':"fA
XN3/NdQ-FtPGQ`**D#qZ`+_oVcGgapBY`kjrJ-RZW_3V8q5C-WeXCgUZ?H61cR
mI57-DGq*E2a+U=;g4kF?ODNUZ'kjAV42^NN,e6>ls5
`@VJ]pjlh9mZ"j">lX6N/t/_W$b0ZLGQU2#Id*fL'.S]\#KkA8PBtSelSiL4V;i\2
I!YiGe^Z8V^F5lB<4Ytl8[`A"T]]B53t>@dm?m:uu&nT&>o^h=>ptdduR:0W&(O
;9L^P;HLt2A[>tUCj7]L/^+*-HFt@*E;4V--7th@SnHI6N\rld_MQk`=(E+KBE6-m
Xp+Q4S43CO+f$!mQ4qdLLkC(+K[O`III;o`!JVnpX0
cN)pB'rC~>
endstream
endobj
73 0 obj
[/Indexed/DeviceRGB 255 72 0 R]
endobj
72 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
128 0 obj
<>
endobj
97 0 obj
<>
endobj
47 0 obj
<>
endobj
92 0 obj
<>
endobj
145 0 obj
<>
endobj
175 0 obj
<>
endobj
93 0 obj
<>
endobj
120 0 obj
<>stream
HUiPSYBaX$eJEDTܪ]PEPA"D,@BB d3 bPqCe[EvGij*g&gjԩ9;uSu1M
jv@ȗ]/MHf>=ŁɎ#Ύ4@_uߥ3NNk>>-OZ%ʐ)Rެ_pG\ BD|^\"%E8AOBx/ዳO^O*NHĩ<^ ]$gy!y"1O`IdA A,K30{0\S1c#OJ8``32c^;x0FC2Ejߜ:8._8'9q tqy泟Mvb=n!nkݟO&S;7rM.P!g+Ƕȍ:B'Kz\d&&]ZaI>xcZb2e_YqG*'4``+h7`ѫ4W@ڈYeojJrIG^6S3#3.9Iq&?0뻍rDJl?d%r$P!X~ZB&639~{ƥ5lᣜ8x,GSD{kәޠgcLzͻ(.lu6JBjvf,ٮ\2j4^w+tbz|C~4b }uGݹӝN]M"?ď5k#Kh%wYnDM0
ߑLˑjH(2o?y;0A`멶ֆ;{7lrzi7+7u9|o^~%N]9lV?BSYVSŭ3h䁦E>1$ؼC]/.E9QA.ޡn>E%`FFKFnʙ?.xY-YKa(}@DÊDic
AhľzOiБ&Tdy2رh\{]C{p+ꔃe0&J&am%Yh;h:zSs4(̻7 aN`h~48ZTCh!V!]3#_9hwY}@#1z;&KEKZWM\4""c3ZmjqNI!*x }9fvⴛ-sA$JF̬QCG9 c660oofZ˝A'֡iid&P4
7d=4};emmTq>w!#XmYL49EP}k